Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients
Background. Multiple myeloma (MM) and its therapies may induce a severely compromised humoral immunity. We have performed a longitudinal analysis of IgG-antibody responses against influenza virus (FLU) and tetanus toxoid (TT) as surrogate markers for the B cell-mediated immunity in MM patients. Meth...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2012/134081 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850225990468370432 |
|---|---|
| author | Sebastian Kobold Tim Luetkens Britta Marlen Bartels Yanran Cao York Hildebrandt Orhan Sezer Henrike Reinhard Julia Templin Katrin Bartels Nesrine Lajmi Friedrich Haag Carsten Bokemeyer Nicolaus Kröger Djordje Atanackovic |
| author_facet | Sebastian Kobold Tim Luetkens Britta Marlen Bartels Yanran Cao York Hildebrandt Orhan Sezer Henrike Reinhard Julia Templin Katrin Bartels Nesrine Lajmi Friedrich Haag Carsten Bokemeyer Nicolaus Kröger Djordje Atanackovic |
| author_sort | Sebastian Kobold |
| collection | DOAJ |
| description | Background. Multiple myeloma (MM) and its therapies may induce a severely compromised humoral immunity. We have performed a longitudinal analysis of IgG-antibody responses against influenza virus (FLU) and tetanus toxoid (TT) as surrogate markers for the B cell-mediated immunity in MM patients. Methods. 1094 serum samples of 190 MM patients and samples from 100 healthy donors were analyzed by ELISA for FLU- and TT-specific antibodies. Results. MM patients evidenced lower levels of FLU- and TT-specific antibodies than healthy controls (P<0.001). Immunoreactivity decreased with progressing disease and worsening clinical status. Levels of FLU- and TT-specific antibodies increased shortly (0-6 months) after alloSCT (P<0.001), a time-period during which intravenous immunoglobulin (IVIG) is routinely applied. Thereafter, antibody concentrations declined and remained suppressed for 3 years in the case of FLU-specific and for more than 5 years in the case of TT-specific antibodies. Conclusions. We found that MM is associated with a profound disease- and therapy-related immunosuppression, which is compensated for a few months after alloSCT, most likely by application of IVIG. This and the differences regarding the recovery of anti-FLU and anti-TT antibody titers during the following years need to be taken into account for optimizing IVIG application and immunization after alloSCT. |
| format | Article |
| id | doaj-art-52c3ade030e34cab8f02a573767cf598 |
| institution | OA Journals |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-52c3ade030e34cab8f02a573767cf5982025-08-20T02:05:12ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/134081134081Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma PatientsSebastian Kobold0Tim Luetkens1Britta Marlen Bartels2Yanran Cao3York Hildebrandt4Orhan Sezer5Henrike Reinhard6Julia Templin7Katrin Bartels8Nesrine Lajmi9Friedrich Haag10Carsten Bokemeyer11Nicolaus Kröger12Djordje Atanackovic13Department of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyInstitute for Immunology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Internal Medicine II, and Department of Oncology, Hematology, Bone Marrow Transplantation Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyBackground. Multiple myeloma (MM) and its therapies may induce a severely compromised humoral immunity. We have performed a longitudinal analysis of IgG-antibody responses against influenza virus (FLU) and tetanus toxoid (TT) as surrogate markers for the B cell-mediated immunity in MM patients. Methods. 1094 serum samples of 190 MM patients and samples from 100 healthy donors were analyzed by ELISA for FLU- and TT-specific antibodies. Results. MM patients evidenced lower levels of FLU- and TT-specific antibodies than healthy controls (P<0.001). Immunoreactivity decreased with progressing disease and worsening clinical status. Levels of FLU- and TT-specific antibodies increased shortly (0-6 months) after alloSCT (P<0.001), a time-period during which intravenous immunoglobulin (IVIG) is routinely applied. Thereafter, antibody concentrations declined and remained suppressed for 3 years in the case of FLU-specific and for more than 5 years in the case of TT-specific antibodies. Conclusions. We found that MM is associated with a profound disease- and therapy-related immunosuppression, which is compensated for a few months after alloSCT, most likely by application of IVIG. This and the differences regarding the recovery of anti-FLU and anti-TT antibody titers during the following years need to be taken into account for optimizing IVIG application and immunization after alloSCT.http://dx.doi.org/10.1155/2012/134081 |
| spellingShingle | Sebastian Kobold Tim Luetkens Britta Marlen Bartels Yanran Cao York Hildebrandt Orhan Sezer Henrike Reinhard Julia Templin Katrin Bartels Nesrine Lajmi Friedrich Haag Carsten Bokemeyer Nicolaus Kröger Djordje Atanackovic Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients Clinical and Developmental Immunology |
| title | Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients |
| title_full | Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients |
| title_fullStr | Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients |
| title_full_unstemmed | Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients |
| title_short | Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients |
| title_sort | longitudinal analysis of tetanus and influenza specific igg antibodies in myeloma patients |
| url | http://dx.doi.org/10.1155/2012/134081 |
| work_keys_str_mv | AT sebastiankobold longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT timluetkens longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT brittamarlenbartels longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT yanrancao longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT yorkhildebrandt longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT orhansezer longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT henrikereinhard longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT juliatemplin longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT katrinbartels longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT nesrinelajmi longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT friedrichhaag longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT carstenbokemeyer longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT nicolauskroger longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients AT djordjeatanackovic longitudinalanalysisoftetanusandinfluenzaspecificiggantibodiesinmyelomapatients |